

CONTENTS

CHAPTER 1 Fundamentals of DNA, Chromosomes, and Cells

1.1 The Structure and Function of Nucleic Acids

General concepts: the genetic material, genomes, and genes

The underlying chemistry of nucleic acids

Base pairing and the double helix

DNA replication and DNA polymerases

Genes, transcription, and the central dogma of molecular biology

1.2 The Structure and Function of Chromosomes

Why we need highly structured chromosomes, and how they are organized

Chromosome function: replication origins, centromeres, and telomeres

Centromeres

Replication origins

Telomeres

1.3 DNA and Chromosomes in Cell Division and the Cell Cycle

Differences in DNA copy number between cells

Mitochondrial DNA copy number

The cell cycle and segregation of replicated chromosomes and DNA molecules

Changes in cell chromosome number and DNA content

Mitochondrial DNA replication and segregation

Mitosis: the usual form of cell division

Meiosis: a specialized reductive cell division giving rise to sperm and egg cells

Pairing of paternal and maternal homologs (synapsis)

Recombination

Why each of our gametes is unique

Summary

Questions

Further Reading

CHAPTER 2 Fundamentals of Gene Structure, Gene Expression, and Human Genome Organization

2.1 Protein-Coding Genes: Structure and Expression

Gene organization: exons and introns

RNA splicing: stitching together the genetic information in exons

The evolutionary value of RNA splicing

Translation: decoding messenger RNA to make a polypeptide

The process of translation

Transfer RNA as an adaptor RNA

Untranslated regions and 5' cap and 3' poly(A) termini

From newly synthesized polypeptide to mature protein

Chemical modification

Folding

Cleavage and transport

Binding of multiple polypeptide chains

2.2 RNA Genes and Noncoding RNA

The extraordinary secondary structure and versatility of RNA

RNAs that act as specific regulators: from quirky exceptions to the mainstream

Long ncRNAs

Tiny ncRNAs

Competing endogenous RNAs

2.3 Working Out the Details of Our Genome and What They Mean

The Human Genome Project: working out the details of the nuclear genome

Interrogating our genome

What the sequence didn't tell us

Identifying genes and other functionally important DNA elements through evolutionary conservation

Identifying genes and their orthologs

Sequence conservation due to selection

The ENCODE Project: functional assays to determine what our genome does

Transcript analysis

Biochemical signatures

The outcome

2.4 The Organization and Evolution of the Human Genome

A brief overview of the evolutionary mechanisms that shaped our genome

How much of our genome is functionally significant?

Estimating functional constraint

The mitochondrial genome: economical usage but limited autonomy

Gene distribution in the human genome

The extent of repetitive DNA in the human genome

The organization of gene families

The significance of gene duplication and repetitive coding DNA

Dosage

Novel genetic variants

Highly repetitive noncoding DNA in the human genome

Transposon-derived repeats in the human genome

Summary

Questions

Further Reading

CHAPTER 3 Principles Underlying Core DNA Technologies

3.1 DNA Cloning and PCR

DNA cloning: fractionating and purifying DNA by transforming cells with recombinant DNAs

Amplification

Vector molecules

Physical clone separation

Making recombinant DNA

DNA libraries and the uses and limitations of DNA cloning

The basics of the polymerase chain reaction (PCR)

Quantitative PCR and real-time PCR

3.2 Principles of Nucleic Acid Hybridization

Formation of artificial heteroduplexes

Hybridization assays: using known nucleic acids to find related sequences in a test nucleic acid population

Using high and low hybridization stringency

Two classes of hybridization assay

Microarray hybridization: large-scale parallel hybridization to immobilized probes

3.3 Principles of DNA Sequencing

Dideoxy DNA sequencing

Massively parallel DNA sequencing (next-generation sequencing)

Summary

Questions

Further Reading

CHAPTER 4 Principles of Genetic Variation

4.1 Origins of DNA Sequence Variation

Genetic variation arising from endogenous errors in chromosome and DNA function

DNA replication errors

Chromosome segregation and recombination errors

Various endogenous and exogenous sources can cause damage to DNA by altering its chemical structure

Endogenous chemical damage to DNA

Chemical damage to DNA caused by external mutagens

4.2 DNA Repair

Repair of DNA damage or altered sequence on a single DNA strand

Repair of DNA lesions that affect both DNA strands

Repair of DNA interstrand cross-links

Undetected DNA damage, DNA damage tolerance, and translesion synthesis

4.3 The Scale of Human Genetic Variation

DNA variants, polymorphism, and developing a comprehensive catalog of human genetic variation

Single nucleotide variants and single nucleotide polymorphisms

The imprecise cut-off between indels and copy number variants

Microsatellites and other polymorphisms due to variable number of tandem repeats

Structural variation and low copy number variation

Taking stock of human genetic variation

4.4 Functional Genetic Variation and Protein Polymorphism

Most genetic variation has a neutral effect on the phenotype, but a small fraction is harmful

Harmful mutations

Positive Darwinian selection and adaptive DNA changes in human lineages

Adaptations to altered environments

Generating protein diversity by gene duplication and alternative processing of a single gene

Diversity through gene duplication

Post-transcriptionally induced variation

4.5 Extraordinary Genetic Variation in the Immune System

Pronounced genetic variation in four classes of immune system proteins

Random and targeted post-zygotic (somatic) genetic variation

Somatic mechanisms that allow cell-specific production of immunoglobulins and T-cell receptors

Combinatorial diversity via somatic recombination

Additional diversity generation

MHC (HLA) proteins: functions and polymorphism

Class I MHC proteins

Class II MHC proteins

MHC restriction

MHC polymorphism

The medical importance of the HLA system

Transplantation and histocompatibility testing

HLA disease associations

Summary

Questions

Further Reading

CHAPTER 5 Single-Gene Disorders: Inheritance Patterns, Phenotype Variability, and Allele Frequencies

5.1 Introduction: Terminology, Electronic Resources, and Pedigrees

Background terminology and electronic resources with information on single-gene disorders

Alleles and allele combinations

Dominant and recessive phenotypes

Electronic information on monogenic disorders

Investigating family history of disease and recording pedigrees

5.2 The Basics of Mendelian and Mitochondrial DNA Inheritance Patterns 120

Autosomal dominant inheritance	120
Autosomal recessive inheritance	121
Consanguinity	121
Disease-related phenotypes in carriers	122
X-linked inheritance and X-chromosome inactivation	122
X-chromosome inactivation	124
X-linked recessive inheritance	124
X-linked dominant inheritance	125
Pseudoautosomal and Y-linked inheritance	126
Pseudoautosomal inheritance	127
Y-linked inheritance	127
Matrilineal inheritance for mitochondrial DNA disorders	128
Variable heteroplasmy and clinical variability	128

5.3 Uncertainty, Heterogeneity, and Variable Expression of Mendelian Phenotypes 129

Difficulties in defining the mode of inheritance in small pedigrees	130
New mutations and mosaicism	130
Post-zygotic mutations and mosaicism	131
Heterogeneity in the correspondence between phenotypes and the underlying genes and mutations	131
Locus heterogeneity	132
Allelic and phenotypic heterogeneity	133
Non-penetrance and age-related penetrance	134
Variable age at onset in late-onset disorders	134
Variable expression of Mendelian phenotypes within families	135
Imprinting	136
Anticipation	136

5.4 Allele Frequencies in Populations 137

Allele frequencies and the Hardy–Weinberg law	138
The Hardy–Weinberg law	138
Applications and limitations of the Hardy–Weinberg law	139
Nonrandom mating	140
Ways in which allele frequencies change in populations	140
Population bottlenecks and founder effects	141
Mutation versus selection in determining allele frequencies	142
Heterozygote advantage: when natural selection favors carriers of recessive disease	144
Distinguishing heterozygote advantage from founder effects	145

Summary 145

Questions 147

Further Reading 148

CHAPTER 6 Principles of Gene Regulation and Epigenetics 149

6.1 Genetic Regulation of Gene Expression 151

Promoters: the major on–off switches in genes	151
Modulating transcription, tissue-specific regulation, enhancers, and silencers	152
Enhancers, silencers, and insulator elements	152
Transcription factor binding	153

Genetic regulation during RNA processing: RNA splicing and RNA editing	154
Regulation of RNA splicing	154
Alternative splicing	155
RNA editing	156

Translational regulation by <i>trans</i> -acting regulatory proteins	156
--	-----

Post-transcriptional gene silencing by microRNAs	157
--	-----

Repressing the repressors: competing endogenous RNAs sequester miRNA	159
Circular RNAs as abundant miRNA sponges	160

6.2 Chromatin Modification and Epigenetic Factors in Gene Regulation 160

Changes in chromatin structure producing altered gene expression	161
--	-----

Modification of histones in nucleosomes	162
---	-----

The effect of modified histones and histone variants on chromatin structure	164
---	-----

The function of DNA methylation in mammalian cells	165
--	-----

DNA methylation: mechanisms, heritability, and global roles during early development and gametogenesis	166
--	-----

DNA methylation mechanism	166
---------------------------	-----

DNA methylation in early development and gametogenesis	166
--	-----

Noncoding RNAs in epigenetic regulation	169
---	-----

<i>Cis</i> - and <i>trans</i> -acting regulation	169
--	-----

Genomic imprinting: differential expression of maternally and paternally inherited alleles	170
--	-----

Extent and significance of genome imprinting	171
--	-----

Establishing sex-specific imprints by differential methylation	171
--	-----

X-chromosome inactivation: compensating for sex differences in gene dosage	173
--	-----

X-chromosome counting and inactivation choices	174
--	-----

<i>XIST</i> RNA and initiation of X-inactivation	174
--	-----

Escaping X-inactivation	175
-------------------------	-----

Epigenomes and dissecting the molecular basis of epigenetic regulation	175
--	-----

The International Human Epigenetic Consortium (IHEC)	176
--	-----

6.3 Abnormal Epigenetic Regulation in Mendelian Disorders and Uniparental Disomy 176

Principles of epigenetic dysregulation	176
--	-----

'Chromatin diseases' due to mutations in genes specifying chromatin modifiers	178
---	-----

Rett syndrome: a classical chromatin disease	178
--	-----

Disease resulting from dysregulation of heterochromatin	179
---	-----

Inappropriate gene silencing	179
------------------------------	-----

Heterochromatin reduction	179
---------------------------	-----

Uniparental disomy and disorders of imprinting	180
--	-----

Abnormal gene regulation at imprinted loci	181
--	-----

Imprinting and assisted reproduction	183
--------------------------------------	-----

Summary 186

Questions 187

Further Reading 188

CHAPTER 7 Genetic Variation Producing Disease-Causing Abnormalities in DNA and Chromosomes

7.1 How Genetic Variation Results in Disease

7.2 Pathogenic Nucleotide Substitutions and Tiny Insertions and Deletions

Pathogenic single nucleotide substitutions within coding sequences

- Relative frequencies of silent and amino-acid-replacing substitutions
- Conservative substitution: replacing an amino acid by a similar one
- Nonconservative substitutions: effects on the polypeptide/protein

Mutations producing premature termination codons and aberrant RNA splicing

- Pathogenic splicing mutations

Genesis and frequency of pathogenic point mutations

- Mutation rates in the human genome
- Total pathogenic load
- Effect of parental age and parental sex on germ-line mutation rates
- Paternal-age-effect disorders and selfish spermatogonial selection

Surveying and curating point mutations that cause disease

- Point mutations in coding DNA
- Point mutations in RNA genes and other noncoding DNA
- Databases of human pathogenic mutations

7.3 Moderate- to Large-Scale Pathogenic Mutations Triggered by Repetitive DNA

Pathogenic expansion of arrays of short tandem

oligonucleotide repeats in coding DNA

- Pathogenic polyalanine expansion
- Unstable expansion of CAG repeats encoding polyglutamine

Pathogenic unstable expansion of short noncoding tandem repeats

Pathogenic sequence exchanges between chromatids at mispaired tandem repeats

Pathogenic sequence exchanges between distant repeats in nuclear DNA and in mtDNA

- Chromosome microdeletions and microduplications
- Deletions resulting from direct repeats in mtDNA
- Intrachromatid recombination between inverted repeats

7.4 Chromosome Abnormalities

Structural chromosomal abnormalities

- Large-scale duplications, deletions, and inversions
- Chromosomal translocations
- Isochromosomes

Chromosomal abnormalities involving gain or loss of complete chromosomes

- Polyploidy
- Aneuploidy
- Maternal age effects in Down syndrome
- Mixoploidy

7.5 The Effects of Pathogenic Variants on the Phenotype

Mutations affecting how a single gene works:

loss-of-function and gain-of-function

- Loss-of-function mutations
- Gain-of-function mutations

The effect of pathogenic variants depends on how the products of alleles interact: dominance and recessiveness revisited

- Loss-of-function versus gain-of-function mutations in recessive and dominant disorders
- Striking loss of function produced by dominant-negative effects in heterozygotes

Gain-of-function and loss-of-function mutations in the same gene produce different phenotypes

Multiple gene dysregulation resulting from aneuploidies and point mutations in regulatory genes

- Segmental aneuploidies
- Contiguous gene syndromes

7.6 A Protein Structure Perspective of Molecular Pathology

Pathogenesis arising from protein misfolding

- Regulation of protein folding
- Aberrant protein folding causing disease

How protein aggregation can result in disease

- Sickle-cell anemia: disruptive protein fibers
- α_1 -Antitrypsin deficiency: inclusion bodies and cell death
- Seeding by aberrant protein templates

7.7 Genotype–Phenotype Correlations and Why Monogenic Disorders Are Often Not Simple

The difficulty in getting reliable genotype–phenotype correlations

- Exceptional versus general reasons for poor genotype–phenotype correlations

Modifier genes and environmental factors: common explanations for poor genotype–phenotype correlations

- Modifier genes: the example of β -thalassemia
- Environmental factors influencing the phenotype of genetic disorders

Summary

Questions

Further Reading

CHAPTER 8 Identifying Disease Genes and Genetic Susceptibility to Complex Disease

8.1 Identifying Genes in Monogenic Disorders

- Position-dependent strategies
- The final step: mutation screening

Linkage analysis to map genes for monogenic disorders to defined subchromosomal regions

- Human genetic maps
- Principle of genetic linkage
- Human meiotic recombination frequencies

Standard genomewide linkage analyses	252	Protective factors and the basis of genetic resistance to infectious disease	293
Autozygosity mapping in extended inbred families	255	Gene–gene interaction (epistasis) in complex disease	295
Chromosome abnormalities and other large-scale mutations as routes to identifying disease genes	255	Gene–environment interactions in complex disease	296
Exome sequencing: let's not bother getting a position for disease genes!	256	A plethora of 'environmental factors'	296
		Prospective cohort studies	297
8.2 Approaches to Mapping and Identifying Genetic Susceptibility to Complex Disease	259	Epigenetics in complex disease and aging: significance and experimental approaches	297
The polygenic and multifactorial nature of common diseases	259	Experimental investigations	300
Complexities in disease risk prediction	259	Epigenetic changes during aging	300
Difficulties with lack of penetrance and phenotype classification in complex disease	261	Epigenetic changes in monozygotic twins	301
Phenotype classification and phenocopies	261	The developmental origins of adult health and disease	301
Estimating the contribution made by genetic factors to the variance of complex diseases	262	Transgenerational epigenetic effects	302
Family studies	263	Summary	302
Adoption and twin studies	263	Questions	305
Variation in the genetic contribution to disorders	263	Further Reading	306
Linkage analyses to seek out genes for complex diseases	264		
Parametric linkage analyses in Mendelian subsets	264	CHAPTER 9 Genetic Approaches to Treating Disease	309
Nonparametric and affected sib-pair linkage analysis	265		
Identifying the disease-susceptibility gene	267	9.1 An Overview of Treating Genetic Disease and of Genetic Treatment of Disease	310
The principle of allelic association	268	Three different broad approaches to treating genetic disorders	310
Linkage disequilibrium as the basis of allelic associations	269	Augmentation therapy for genetic deficiencies	310
Sharing of ancestral chromosome segments	272	Applicability of molecular augmentation therapy	311
How genomewide association studies are carried out	273	Treatment for disorders producing positively harmful effects	312
The transmission disequilibrium test	275	Treatment by altering disease susceptibility	312
Moving from candidate subchromosomal region to identify causal genetic variants in complex disease	276	Very different treatment options for different inborn errors of metabolism	313
Identifying causal variants	277	Two broad phenotype classes	313
The limitations of GWA studies and the issue of missing heritability	278	Augmentation therapy	313
The relative contributions of common and rare variants to complex disease susceptibility	279	Treating or preventing harmful effects of elevated metabolites	314
The common disease–common variant hypothesis	280	Mixed success in treatment	314
How common deleterious alleles are maintained	280	Genetic treatment of disease may be conducted at many different levels	316
The common disease–rare variant hypothesis	281		
Copy number variants associated with complex diseases	281	9.2 Genetic Inputs into Treating Disease with Small Molecule Drugs and Therapeutic Proteins	317
CNPs and CNVs in neuropsychiatric disorders	283	Small molecule drugs	318
Recent explosive growth in human population has meant that most coding sequence variants are rare variants	283	New approaches	318
Massively parallel DNA sequencing to identify rare sequence variants associated with complex disease	284	An overview of how genetic differences affect the metabolism and performance of small molecule drugs	319
<i>De novo</i> sequence variants	285	Different stages at which genetic variation influences drug metabolism	319
The overall contribution made by rare variants	285	Phase I and phase II reactions in drug metabolism	320
		Phenotype differences arising from genetic variation in drug metabolism	320
8.3 Our Developing Knowledge of the Genetic Architecture of Complex Disease and the Contributions of Environmental and Epigenetic Factors	286	Genetic variation in cytochrome P450 enzymes in phase I drug metabolism	321
The success and the utility of genomewide association studies	286	Genetic variation in CYP2D6 and its consequences	322
The utility of GWA studies	287	Genetic variation in other cytochrome P450 enzymes	323
Assessment and prediction of disease risk	287	Genetic variation in enzymes that work in phase II drug metabolism	324
New insights into biological pathways in complex diseases may offer new approaches in classifying and treating disease	289	Altered drug responses resulting from genetic variation in drug targets	325
The pathogenesis of inflammatory bowel disease	289	When genotypes at multiple loci in patients are important in drug treatment: the example of warfarin	326
Connections between different disease pathways	293		

Translating genetic advances: from identifying novel disease genes to therapeutic small molecule drugs	327	The prospect of germ-line gene therapy to prevent mitochondrial DNA disorders	366
Cystic fibrosis: not an easy prospect	328	Summary	366
Familial hypercholesterolemia: new and valuable drugs	330	Questions	369
Marfan syndrome: advantages of a mouse model	331	Further Reading	370
Tuberous sclerosis: from a biological pathway to a promising drug	331		
Translating genomic advances and developing generic drugs as a way of overcoming the problem of too few drug targets	332		
Translating genomic advances	332	CHAPTER 10 Cancer Genetics and Genomics	373
Developing generic drugs	332		
Developing different drugs: therapeutic recombinant proteins produced by genetic engineering	333	10.1 Fundamental Characteristics and Evolution of Cancer	373
Genetically engineered therapeutic antibodies with improved therapeutic potential	333	The defining features of unregulated cell growth and cancer	373
Genetically engineered antibodies	334	Cancer as a battle between natural selection operating at the level of the cell and of the organism	375
Intrabodies	335	The balance between cell proliferation and cell death	376
		Why we do not all succumb to cancer	377
9.3 Principles of Gene and Cell Therapy	336	Cancer cells acquire several distinguishing biological characteristics during their evolution	377
Two broad strategies in somatic gene therapy	337	The initiation and multi-stage nature of cancer evolution and why most human cancers develop over many decades	380
The delivery problem: designing optimal and safe strategies for getting genetic constructs into the cells of patients	338	Clonal expansion and successive driver mutations	381
Efficiency and safety aspects	338	Cancer development through accelerated mutation	382
Different ways of delivering therapeutic genetic constructs, and the advantages of <i>ex vivo</i> gene therapy	342	Mutation accumulation and age of cancer onset	382
<i>In vivo</i> and <i>ex vivo</i> gene therapy	342	Intratumor heterogeneity arises through cell infiltration, clonal evolution, and differentiation of cancer stem cells	383
Nonviral systems for delivering therapeutic genetic constructs: safety at the expense of efficiency	343	10.2 Oncogenes and Tumor Suppressor Genes	385
Viral delivery of therapeutic gene constructs: relatively high efficiency but safety concerns	345	Two fundamental classes of cancer gene	385
Integrating and non-integrating viral vectors	345	Viral oncogenes and the natural roles of cellular oncogenes	387
The importance of disease models for testing potential therapies in humans	346	Oncogene activation: chromosomal rearrangements resulting in increased gene expression or gain-of-function mutations	388
When rodent disease models can be inadequate	347	Activation by gene amplification	388
		Translocation-induced gene activation	389
9.4 Gene Therapy for Inherited Disorders and Infectious Disease: Practice and Future Directions	350	Gain-of-function mutations	391
Multiple successes for <i>ex vivo</i> gene augmentation therapy targeted at hematopoietic stem cells	350	Tumor suppressor genes: normal functions, the two-hit paradigm, and loss of heterozygosity in linked markers	391
Safety issues in gammaretroviral integration	351	Familial cancers and the two-hit paradigm	391
Increased safety profiles using lentiviral vectors	353	Loss of heterozygosity	393
<i>In vivo</i> gene therapy: approaches, barriers, and recent successes	354	The key roles of gatekeeper tumor suppressor genes in suppressing G1-S transition in the cell cycle	394
Delivery using adenovirus and adeno-associated virus vectors	354	The additional role of p53 in activating different apoptosis pathways to ensure that rogue cells are destroyed	395
Amenability of disorders to <i>in vivo</i> gene therapy	354	Rare familial cancers and the need for a revision of the classical two-hit tumor suppressor paradigm	397
Two recent examples of successful <i>in vivo</i> gene therapy	355	Haploinsufficiency and gain-of-function mutations	398
Complex disease applications: the example of Parkinson disease	355	A revised model for tumor suppression	398
RNA targeting therapies: gene silencing by RNA interference and modulation of RNA splicing	357	The significance of miRNAs and long noncoding RNAs in cancer	398
Gene-silencing therapy using RNA interference	357	10.3 Genomic Instability and Epigenetic Dysregulation in Cancer	399
Modulation of splicing	357	An overview of genome and epigenome instability in cancer	399
Future prospects and new approaches: therapeutic stem cells, cell reprogramming, and genome editing	359	Different types of chromosomal instability in cancer	402
Therapeutic embryonic stem cells	362	Chromothripsis	402
Therapeutic induced pluripotent stem cells	362	Telomeres and chromosome stability	403
Therapeutic cell reprogramming by transdifferentiation	363		
Therapeutic genome editing	363		

Deficiency in mismatch repair results in unrepaired replication errors and global DNA instability	404	Autosomal aneuploidies	436
The mechanism of mismatch repair	405	Sex chromosome aneuploidies	437
Consequences of defective mismatch repair	405	Noninvasive fetal aneuploidy screening	438
Epigenetic dysregulation in cancer and its effects on gene expression and genome stability	406	Detecting large-scale DNA copy number changes with the use of microarray-based genomic copy number analysis	438
Aberrant DNA methylation	407	Array comparative genome hybridization (aCGH)	438
Genome–epigenome interactions	407	SNP microarray hybridization	439
10.4 New Insights from Genomewide Studies of Cancers	408	Unclassified variants and incidental findings	440
Genomewide gene expression screens to enable clinically useful gene expression signatures	408	The need for conventional karyotyping and chromosome FISH (fluorescence <i>in situ</i> hybridization)	441
Clinical applications	409	Chromosome FISH	441
Genome sequencing reveals extraordinary mutational diversity in tumors and insights into cancer evolution	411	DNA technologies for detecting pathogenic changes in copy number of specific DNA sequences	442
Mutation number	411	Multiplex ligation-dependent probe amplification (MLPA)	445
Mutational processes and cancer evolution	412	11.3 The Technology of Genetic Testing for Small-Scale DNA Changes	446
Intertumor and intratumor heterogeneity	413	Scanning for undefined point mutations in single and multiple genes, and in whole exomes and genomes	447
Defining the landscape of driver mutations in cancer and the quest to establish a complete inventory of cancer-susceptibility genes	414	Gene-specific microarray-based mutation scanning	447
Cancer gene and driver mutation distribution	416	Multiplex mutation scanning: multiple genes to whole exomes	447
Novel cancer-susceptibility genes	417	Interpreting sequence variants and the problem of variants of uncertain clinical significance	451
Non-classical cancer genes linking metabolism to the epigenome	417	Mutation interpretation and databases	452
10.5 Genetic Inroads into Cancer Therapy	418	Variants of uncertain clinical significance	453
Treatment or prevention?	419	Scanning for possible pathogenic changes in cytosine methylation patterns	454
The efficacy of cancer therapy	419	Technologies for genotyping a specific point mutation or SNP	455
The different biological capabilities of cancer cells afford many different potential therapeutic entry points	420	Multiplex genotyping of specific disease-associated variants as a form of mutation scanning	456
Targeted cancer therapy after genetic studies define a precise molecular focus for therapy	422	11.4 Genetic Testing: Organization of Services and Practical Applications	458
The molecular basis of tumor recurrence and the evolution of drug resistance in cancers	423	Genetic testing of affected individuals and their close relatives	458
The basis of tumor recurrence	423	Cascade testing	459
The evolution of drug resistance	424	Traditional prenatal diagnosis uses fetal tissue samples recovered by an invasive procedure	460
Combinatorial drug therapies	424	Preimplantation genetic testing often analyzes a single cell in the context of assisted reproduction (<i>in vitro</i> fertilization)	460
Summary	424	Noninvasive prenatal testing (NIPT) and whole fetal genome screening	464
Questions	427	Technological breakthroughs	464
Further Reading	427	From fetal aneuploidy screening to genome screening	465
CHAPTER 11 Genetic Testing from Genes to Genomes, and the Ethics of Genetic Testing and Therapy	431	Pre-symptomatic and predictive testing for single-gene disorders in asymptomatic individuals	465
11.1 An Overview of Genetic Testing	432	Pre-symptomatic testing without medical intervention	466
Evaluating genetic tests	432	An overview of the different types and levels of genetic screening	466
Genetic testing: direct genotyping assays, mutation scanning, downstream assays, and indirect linkage analyses	432	Maternal screening for fetal abnormalities	467
Indirect linkage analyses	433	Newborn screening to allow early medical intervention	469
Different levels at which genetic testing can be carried out	434	Benefits versus disadvantages	470
11.2 The Technology of Genetic Testing for Chromosome Abnormalities and Large-Scale DNA Changes	435	Carrier screening for disease prevention in serious autosomal recessive disorders	470
Detecting aneuploidies with the use of quantitative fluorescence PCR	436	Screening for β -thalassemia	470
Principles of quantitative fluorescence PCR	436	Community screening for Tay–Sachs disease	471
		New genomic technologies are beginning to transform cancer diagnostics	471
		Multiplex testing using targeted genome sequencing	472
		Noninvasive cancer testing	473

CHAPTER 1

Genetic testing for complex disease and direct-to-consumer genetic testing	474
--	-----

11.5 Ethical Considerations and Societal Impact of Genetic Testing and Genetic Approaches to Treating Disease 474

Consent issues in genetic testing	475
Consent issues in testing children	475

Problems with sharing of genetic information and the limits on confidentiality	476
--	-----

Ethical and societal issues in prenatal diagnosis and testing	477
Preimplantation genetic diagnosis (PGD)	477

Restrictions on genetic testing as a result of gene patenting	477
---	-----

Genetic discrimination and ethical, societal, and practical issues raised by clinical genomewide sequencing	478
---	-----

Incidental findings	479
---------------------	-----

Neonatal genome sequencing	481
----------------------------	-----

The ethics of genetic manipulation of the germ line to prevent disease or to enhance normal human traits	482
--	-----

Genetic enhancement and designer babies	482
---	-----

Ethical considerations and societal sensitivity to three-person IVF treatment for mitochondrial DNA disorders	483
---	-----

Summary	484
----------------	------------

Questions	486
------------------	------------

Further Reading	487
------------------------	------------

Glossary	489
-----------------	------------

Index	503
--------------	------------